Baseline demographics and disease-related characteristics of patients
| Characteristic . | Bor-HDM (n = 54) . |
|---|---|
| Sex, M/F, n | 31/23 |
| Median age, y (range) | 58 (40-65) |
| Isotype, n (%) | |
| IgG | 37 (69) |
| IgA | 10 (18) |
| LC | 5 (9) |
| Others | 2 (4) |
| ISS stage, n (%) | |
| I | 29 (54) |
| II | 13 (24) |
| III | 12 (22) |
| Durie-Salmon stage, n | |
| I | 8 |
| II | 8 |
| III | 43 |
| Median creatinine level, mg/dL (range) | 1.02 (0.55-7.43) |
| Median calcium level, mmol/L (range) | 2.3 (2.0-3.5) |
| Median β2-microglobulin level, mg/L (range) | 3.0 (1.7-15.7) |
| Median albumin level, g/L (range) | 38 (18-52) |
| Median hemoglobin level, g/dL (range) | 10.0 (5.0-11.2) |
| Median bone marrow plasma cells, % (range) | 30 (4-90) |
| FISH analysis (n = 49), n (%) | |
| del(13q) | 23 (47) |
| del(17p) | 3 (6) |
| t(4;14) | 6 (12) |
| Frontline treatments, n (%) | |
| VAD | 29 (54) |
| Bor/Dex | 18 (33) |
| More than 2 lines of therapy | 7 (13) |
| Characteristic . | Bor-HDM (n = 54) . |
|---|---|
| Sex, M/F, n | 31/23 |
| Median age, y (range) | 58 (40-65) |
| Isotype, n (%) | |
| IgG | 37 (69) |
| IgA | 10 (18) |
| LC | 5 (9) |
| Others | 2 (4) |
| ISS stage, n (%) | |
| I | 29 (54) |
| II | 13 (24) |
| III | 12 (22) |
| Durie-Salmon stage, n | |
| I | 8 |
| II | 8 |
| III | 43 |
| Median creatinine level, mg/dL (range) | 1.02 (0.55-7.43) |
| Median calcium level, mmol/L (range) | 2.3 (2.0-3.5) |
| Median β2-microglobulin level, mg/L (range) | 3.0 (1.7-15.7) |
| Median albumin level, g/L (range) | 38 (18-52) |
| Median hemoglobin level, g/dL (range) | 10.0 (5.0-11.2) |
| Median bone marrow plasma cells, % (range) | 30 (4-90) |
| FISH analysis (n = 49), n (%) | |
| del(13q) | 23 (47) |
| del(17p) | 3 (6) |
| t(4;14) | 6 (12) |
| Frontline treatments, n (%) | |
| VAD | 29 (54) |
| Bor/Dex | 18 (33) |
| More than 2 lines of therapy | 7 (13) |
Bor-HDM indicates bortezomib and high-dose melphalan; Ig, immunoglobulin; LC, light chain; ISS, International Staging System; FISH, fluorescence in situ hybridization; VAD, vincristine, Adriamycin, and dexamethasone; Bor/Dex, bortezomib and dexamethasone.